'Not all drugs (and route) are same'

I read with great interest, study by French vasculitis group, the MAINRITSAN 2 trial.¹ The results of this trial again underline our limitations for search of biomarker, which can predict relapse of antineutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitis. I have few concerns about details and analysis regarding induction regime used in the patient study group.

First is about the data provided by authors about the use of cyclophosphamide for remission induction. Previous study has shown that route and cumulative dose used for remission induction can affect relapse in long term.² Risk of relapse is significantly lower when daily oral cyclophosphamide was used for remission induction as against pulse intravenous cyclophosphamide. It would have been clearer if authors had given and compared details of cyclophosphamide therapy used for the last flare, especially when more than 60% of group of participants have received the drug.

Second, a previous study has suggested that ANCA titres predicts relapse in patients in whom rituximab was used for remission induction but this observation was not seen in patient treated with cyclophosphamide.³ In current study group, use of cyclophosphamide was more frequent than rituximab, which may have affected results of study. May be subset analysis between these two groups can be more useful.

Abhishek Arvind Zanwar

Senior Resident, Department of Clinical Immunology, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

Correspondence to Dr Abhishek Arvind Zanwar, Senior Resident, Department of Clinical Immunology, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh 226014, India; abhishek.zanwar@gmail.com

Handling editor Josef S Smolen

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

To cite Zanwar AA. *Ann Rheum Dis* 2019;**78**:e74.

Received 8 May 2018

Accepted 9 May 2018

Published Online First 1 June 2018

► <http://dx.doi.org/10.1136/annrheumdis-2018-213742>

Ann Rheum Dis 2019;**78**:e74. doi:10.1136/annrheumdis-2018-213730

REFERENCES

- 1 Charles P, Terrier B, Perrodeau É, *et al*. French Vasculitis Study Group. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). *Ann Rheum Dis* 2018;**77**:1143–9.
- 2 Harper L, Morgan MD, Walsh M, *et al*. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. *Ann Rheum Dis* 2012;**71**:955–60.
- 3 Fussner LA, Hummel AM, Schroeder DR, *et al*. Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. *Arthritis Rheumatol* 2016;**68**:1700–10.